A Phase 2a, Randomized, Blinded, Paired Psoriasis Lesion, Comparative, Placebo-controlled Study to Evaluate the Safety, Preliminary Efficacy and Pharmacokinetics of Epidermal Administrations of MOL4239 in Adults With Plaque Psoriasis
Phase of Trial: Phase II
Latest Information Update: 29 Dec 2014
At a glance
- Drugs MOL 4239 (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Moleculin
- 22 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 05 Aug 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 15 Apr 2013 New trial record